VIDEO: ADAURA results ‘practice affirming’ for lung cancer subset
Click Here to Manage Email Alerts
Healio spoke with Howard (Jack) West, MD, associate clinical professor of medical oncology at City of Hope Comprehensive Cancer Center, about results from the ADAURA trial presented at ASCO Annual Meeting.
West explained that preliminary data from the trial — which assessed the use of osimertinib (Tagrisso, AstraZeneca) in patients with resected stage IB to IIIA EGFR-mutated non-small cell lung cancer — was previously presented in 2020, and additional data on disease-free survival was published earlier this year.
He noted that the newest results on overall survival were both statistically and clinically significant.
“Unfortunately, in the control arm, the majority of patients did not get osimertinib at crossover,” West said. “This is a global trial; there were different standards in different places. But since 2020, the standard in the U.S. and much of the world has been osimertinib as the clearly preferred best agent for relapsed or metastatic EGFR-mutation-positive disease.”
He added that “we will be debating the ethics of this and whether it’s fair or appropriate for patients who are on a control arm of a trial that is used to change practice in the U.S. and other advantaged health care systems, to make those changes based on trials that give the control arm less than what we would consider the standard of care where we are.”
West noted that while these debates are being considered, “in the meantime, this certainly is practice affirming that there is a real value to osimertinib.”
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts